Detalhe da pesquisa
1.
BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Cell
; 146(6): 904-17, 2011 Sep 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-21889194
2.
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Blood
; 142(14): 1208-1218, 2023 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366170
3.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Lancet Oncol
; 25(5): e205-e216, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697166
4.
Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: Loss of mitochondrial i-tRFHisGTG results in patients' poor treatment outcome.
Br J Haematol
; 204(5): 1790-1800, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38414235
5.
Thrombotic and bleeding complications in patients with AL amyloidosis.
Br J Haematol
; 204(5): 1816-1824, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38321638
6.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
7.
How I treat relapsed multiple myeloma.
Blood
; 139(19): 2904-2917, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007326
8.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Haematologica
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385280
9.
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study.
Haematologica
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38356458
10.
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA.
Am J Hematol
; 99(3): 396-407, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38298023
11.
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 24(7): e293-e311, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414019
12.
Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia.
Int J Cancer
; 152(9): 1947-1963, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36533670
13.
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy.
Br J Haematol
; 203(3): 411-415, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37580907
14.
miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma.
J Transl Med
; 21(1): 245, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37024879
15.
Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Hematol Oncol
; 41(4): 725-732, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36974438
16.
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Ann Hematol
; 102(4): 863-876, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36862168
17.
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies.
Eur J Haematol
; 111(2): 271-278, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37218632
18.
Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.
Am J Hematol
; 98(5): 730-738, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36869876
19.
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
Am J Hematol
; 98(5): 720-729, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36708469
20.
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Future Oncol
; 19(5): 345-353, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36815271